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Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: Effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes Authors: Henriksen JN, et al Summary: Genotyping for the UGT1A1 polymorphism was performed in patients with metastatic renal cell carcinoma (mRCC) who developed liver toxicity during first-line pazopanib treatment. Of 261 patients, 13% developed liver toxicity after a median of 29 days; ALT or bilirubin increase of Grade 4 in 6%, Grade 3 in 50%, Grade 2 in 24%. The authors reported UGT1A1 polymorphism was associated with improved median progression-free survival and improved median overall survival. They noted patients with UGT1A1 polymorphism safely resumed pazopanib at ultra-low doses determined by the degree of liver toxicity and UGT1A1 polymorphism.
Comment: Pharmacogenomics has considerable potential in medicine in general but remains hard to implement in practice. As whole genome sequencing becomes more and more affordable, then one of the "value-adds" might be to gain insight on individual patients experience of different treatments. The hepatic toxicity of pazopanib is infrequent but can be severe. This report indicates that the UGT1A1 gene known to be relevant in irinotecan metabolism also appears to be associated with severe toxicity from pazopanib, and also appears to associate with prognosis. It has been appreciated that patient individualisation of toxicity enables optimisation of treatment outcome using sunitinib; this manuscript suggests that this philosophy might be relevant for pazopanib, but also suggests that alternatives would be safer for some patients. The retrospective cohort study included 54 patients undergoing surgery for urological tumours involving the peridiaphragmatic inferior vena cava up to the level of the right atrium. For a subgroup undergoing curative surgery (n = 32) the prognostic value of a renal cancer score using anaemia, neutrophilia, thrombophilia, hypercalcaemia and Karnofsky performance status <80 was assessed. The researcher reported median overall survival of the whole cohort was 29 months. The median survival of the curative subgroup (n = 32) was 32 months versus 11 months for the cytoreductive subgroup (n = 13; P = 0.14). The median follow-up time was 14 months for patients alive at analysis. Disease-free survival in the curative subgroup was 10 months. The median overall survival by risk category for curative cases, as defined by the study's renal cancer score, was not reached in the favourable risk group (score = 0 points) because there were no patient deaths, 43 months in the intermediate-risk group (score = 1 point), and 18 months in the poor-risk group (score ≥ 2 points; P = 0.005).
Comment: Can you imagine any other cancer that has spread up to a foot away from the primary organ where curative surgery is attempted, and indeed even appears successful in some patients? Renal cell carcinoma is a WEIRD cancer. The heroic surgery for patients with tumour thrombus extending up beyond the diaphragm, even to the right atrium, is well-established in high volume centres, and in this single-institution experience is associated with median survival of ~4 years in patients with curative attempt (M0) surgery. Neoadjuvant VEGFR TKI has not routinely been used in this group of patients; in the modern era combination ICI clinical trials are already underway to examine the optimal sequence of therapies.
Reference: BJU Int 2019 Sep;124(3):462-468 Abstract
Renal mass biopsy is associated with reduction in surgery for early-stage kidney cancer Authors: Patel HD, et al Summary:
The study cohort included 106,258 patients with cT1aN0M0 renal cell carcinoma in the National Cancer Data Base from 2004 to 2015. The investigators found increased use of biopsy (8.0%-15.3%) and nonsurgical management (11.7%-15.6%) over time. They concluded biopsy was significantly associated with use of nonsurgical management .02], P <.001) as well as active surveillance (OR 1.87 [1.69-2.07], P <.001). In addition the probability of undergoing nonsurgical management increased with age and comorbidity. Pathologic tumour upstaging (≥pT3a) occurred more frequently for patients receiving biopsy compared to no biopsy (5.8% vs 3.3%, P <.001).
Comment: Biopsy of incidentally discovered small renal masses (SMR) is safe and has a low rate of complications. With increasing age and comorbidities, people being diagnosed with SRM may have competing comorbidities that make them candidates for consideration of active surveillance. Practice seems to be changing in this direction; biopsy of SRM is increasing with time and this is also associated with a decrease in the use of surgery for these SRM. Knowledge of the underlying diagnosis may give patients and the clinicians more confidence that an expectant management plan is appropriate.
Reference: Urology, 16 Sep 2019 [Epub ahead of print] Abstract
Safety of on-vs off-clamp robotic partial nephrectomy: Per-protocol analysis from the data of the CLOCK randomized trial Authors: Antonelli A, et al Summary: The team analysed data from patients with ≤ 10 renal masses who underwent on-clamp (n=129) vs off-clamp (n=91) robotic partial nephrectomy. The procedures were performed at seven institutions by one experienced surgeon per institution. At univariate analysis, they found no differences regarding intra-operative estimated blood loss, post-operative complications rate, post-operative anaemia, acute kidney injury and positive surgical margins. At multivariate analysis, accounting for tumour diameter and complexity, there was a significant increase in blood loss in the off-clamp group.
Comment: Partial nephrectomy is an attractive surgical option in patients with surgically amenable lesions in an effort to preserve renal mass and thus long-term renal function. However, clamping the renal artery can be associated with hypoxic damage that reduces this benefit. Performing the procedure off-clamp was trialled in this study, which was associated with more blood loss under multivariate analysis, but was otherwise as safe as on-clamp procedures.
Reference: World J Urol, 24 Jul 2019 [Epub ahead of print] Abstract
Impact of rhabdoid differentiation on postoperative outcome for patients with N0M0 renal cell carcinoma Authors: Kim H, et al Summary: Rhabdoid differentiation was identified in 24 of 604 patients with N0M0 renal cell carcinoma (RCC) who had undergone partial or radical nephrectomy. At the median postoperative follow-up period of 53 months, 58 patients (12 with rhabdoid differentiation) showed recurrence and 26 patients (7 with rhabdoid differentiation) had died from RCC. The authors reported rhabdoid differentiation was an independent risk factor of recurrence-free survival (HR 2.81; P = 0.0266) and cancer-specific survival (HR 5.18; P = 0.00182). They noted the presence of rhabdoid differentiation was more important for predicting poor recurrence-free survival and cancer-specific survival in the early pathological tumour (≤pT2) subgroup compared to in the advanced tumour (≥pT3) subgroup.
Comment: This single institution study once again highlights the ominous prognostic implications of discovering rhabdoid differentiation during pathological assessment of localised renal carcinoma. People with rhabdoid features were more than twice as likely to suffer relapse and had a time to recurrence of less than half of patients with non-rhabdoid features. No systemic therapy has been proven to be beneficial in the adjuvant setting in renal cell carcinoma, and while ongoing trials of ICI focus on tumour size and lymph node involvement, it may well be worth considering trials to include patients with this aggressive feature.
Reference: Urol Oncol 2019 Oct;37(10):711-720 Abstract Independent commentary by Dr Craig Gedye BSc(Hons) MBChB FRACP PhD Dr Gedye is a physician/scientist, dual trained as a medical oncologist, clinical trialist and basic science researcher. He works for patients with melanoma, brain, kidney, prostate, testis, and bladder cancer at the Calvary Mater Newcastle, and is the Clinical Research Director at the NSW Statewide Biobank. He chairs the Renal Cancer Subcommittee for ANZUP Cancer Trials Group, and is the coordinating principal investigator for the KeyPAD and UNISON trials. He undertakes translational and basic cancer research at the Hunter Medical Research Institute, University of Newcastle. Dr Gedye's research focus is on cancer heterogeneity; why treatments work for some patients but not others. This challenging research spans the translational spectrum from patient experience to basic science. This study used national cancer registry data to assess the outcomes of 115,365 patients with advanced clear cell renal cell carcinoma (ccRCC); 28,344 papillary RCC and 11,942 chromophobe RCC. The authors reported stage III to IV disease in 25.7% of ccRCC patients, 14.1% of papillary RCC patients, and 14.8% of chromophobe RCC patients. The 5-year overall survival for stage III ccRCC, papillary RCC and chromophobe RCC was 66.9%, 63.6%, and 80.5%, respectively. The 5-year overall survival for stage IV ccRCC, papillary RCC and chromophobe RCC was 19.7%, 13.3%, and 22.0%, respectively. They concluded hazard of death was significantly higher for stage IV papillary RCC vs. ccRCC (HR = 1.29; 95% CI = 1.19, 1.39; P < 0.01) and stage IV chromophobe RCC vs. ccRCC (HR = 1.01; 95% CI = 0.85, 1.21; P = 0.885).
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Comment: While most systemic therapies for advanced RCC are tested and reimbursed for people suffering the clear cell variant, anecdotally we recognise that many patients suffer rare variant or "non-clear cell renal cell carcinoma". This report shows, again, that we ignore these groups at our peril. For every 10 people suffering advanced ccRCC, 2 were identified with advanced papillary RCC and 1 with advanced chromophobe. Whilst these fractions are non exhaustive and the denominator cannot be determined, they at once show that these are "uncommon" variants, not rare. Moreover, this data shows worse survival for patients with papillary RCC versus clear cell, suggesting worse biology. Future trials of advanced renal cell carcinoma should stratify by histology, but should not exclude uncommon variants.
Reference: Urol Oncol 2019 Oct;37(10):727-734 Abstract Sorafenib versus observation following radical metastasectomy for clear-cell renal cell carcinoma: Results from the phase 2 randomized open-label resort study Authors: Procopio G, et al Summary: The RESORT trial included patients with clear-cell mRCC pretreated with nephrectomy and undergoing radical metastasectomy (three or fewer lesions). Patients were randomised within 12 weeks from metastasectomy to sorafenib (n=36) or observation (n=36) for a maximum of 52 weeks. Median recurrence-free survival was 37 months in the observation arm versus 21 months in the sorafenib arm. Adverse event rates were 84% in the sorafenib arm and 31% in the observation arm.
Comment: "I saw my urologist last month and the scans showed a new spot in my [organ] . She referred me to [organ operation surgeon] who cut the spot out. So what should I do now?" An uncommon situation but with the temptation of extrapolating "adjuvant" data from other settings in medical oncology, the hypothesis was raised as to whether an adjuvant VEGFR TKI following metastatectomy to M0 radiological status is worthwhile. And once again, the answer is NO. In this small study the authors should be commended for managing a trial in a rare patient population, but like every other clinical trial using TKI in patients that are radiologically free of disease, there was no clinical benefit and indeed even a trend to worse relapse-free survival in the active treatment arm. Just say NO.
